World's Best Scientists 2026 revealed!
Paola Guglielmelli

Paola Guglielmelli

D-Index & Metrics

Medicine

D-Index
81
Citations
27990
World Ranking
16502
National Ranking
655

Overview

Paola Guglielmelli is affiliated with the University of Florence in Italy and specializes in medicine, with a significant focus on genetics, hematology, and molecular biology. Their research encompasses a wide range of subfields including rheumatology and immunology.

Their work primarily addresses topics related to myeloproliferative neoplasms (MPNs), with an emphasis on diagnosis and treatment strategies. Additional topics covered in their research include acute myeloid leukemia, eosinophilic disorders and syndromes, chronic myeloid leukemia treatments, Kruppel-like factors, hemoglobinopathies, and multiple myeloma research.

Frequent venues for publication include Blood, American Journal of Hematology, Blood Cancer Journal, Leukemia, and HemaSphere.

They have collaborated extensively with other researchers, notably:

  • Alessandro M. Vannucchi
  • Giuseppe Gaetano Loscocco
  • Francesco Mannelli
  • Tiziano Barbui
  • Valerio De Stefano

Some of their recent papers highlight contributions to the understanding of polycythemia vera and essential thrombocythaemia, including:

  • JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis, 2021, Blood Cancer Journal
  • Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera, 2020, British Journal of Haematology
  • Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial, 2021, The Lancet Haematology
  • High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib, 2021, Leukemia
  • Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera, 2022, Blood Cancer Journal

Best Publications

  • Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

    J. Nangalia;C.E. Massie;E.J. Baxter;F.L. Nice

  • Mutations and prognosis in primary myelofibrosis

    Alessandro Maria Vannucchi;Tl Lasho;Paola Guglielmelli;Flavia Biamonte

  • A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

    Francesco Passamonti;Francisco Cervantes;Alessandro Maria Vannucchi;Enrica Morra

  • Long-term survival and blast transformation in molecularly-annotated essential thrombocythemia, polycythemia vera and myelofibrosis

    Ayalew Tefferi;Paola Guglielmelli;Dirk R. Larson;Christy Finke

  • Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.

    Alessandro M. Vannucchi;Elisabetta Antonioli;Paola Guglielmelli;Alessandro Rambaldi

  • Effect of Mutation Order on Myeloproliferative Neoplasms

    Christina A. Ortmann;David G. Kent;Jyoti Nangalia;Yvonne Silber

  • The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.

    Tiziano Barbui;Jürgen Thiele;Heinz Gisslinger;Hans Michael Kvasnicka

  • Classification and Personalized Prognosis in Myeloproliferative Neoplasms.

    Jacob Grinfeld;Jyoti Nangalia;E Joanna Baxter;David C Wedge

  • MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.

    Paola Guglielmelli;Terra L. Lasho;Giada Rotunno;Mythri Mudireddy

  • Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

    Giada Rotunno;Carmela Mannarelli;Paola Guglielmelli;Annalisa Pacilli

  • Prospective identification of high-risk polycythemia vera patients based on JAK2 V617F allele burden

    Alessandro Maria Vannucchi;Elisabetta Antonioli;Paola Guglielmelli;G. Longo

  • Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

    Elisa Rumi;Daniela Pietra;Cristiana Pascutto;Paola Guglielmelli

  • Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments

    Valerio De Stefano;Tommaso Za;Elena Rossi;Alessandro M. Vannucchi

  • IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis

    A Tefferi;T L Lasho;O Abdel-Wahab;P Guglielmelli

  • Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.

    A M Vannucchi;E Antonioli;P Guglielmelli;A Pardanani

  • The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.

    Paola Guglielmelli;Terra L. Lasho;Giada Rotunno;Joannah Score

  • Advances in understanding and management of myeloproliferative neoplasms.

    Alessandro M. Vannucchi;Paola Guglielmelli;Ayalew Tefferi

  • MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis

    Ayalew Tefferi;Paola Guglielmelli;Terra L. Lasho;Naseema Gangat

  • Targeted deep sequencing in polycythemia vera and essential thrombocythemia

    Ayalew Tefferi;Terra L. Lasho;Paola Guglielmelli;Christy M. Finke

  • CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients

    A Tefferi;P Guglielmelli;T L Lasho;G Rotunno

Frequent Co-Authors

Alessandro M. Vannucchi
Alessandro M. Vannucchi University of Florence
Tiziano Barbui
Tiziano Barbui FROM-Fondazione per la Ricerca Ospedale di Bergamo
Alberto Bosi
Alberto Bosi University of Florence
Alessandro Rambaldi
Alessandro Rambaldi University of Milan
Mario Cazzola
Mario Cazzola University of Pavia
Giovanni Barosi
Giovanni Barosi University of Pavia
Francesco Passamonti
Francesco Passamonti University of Milan
Ayalew Tefferi
Ayalew Tefferi Mayo Clinic
Daniela Pietra
Daniela Pietra University of Pavia
Guido Finazzi
Guido Finazzi Mario Negri Institute for Pharmacological Research

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in Medicine opens doors to a wide array of related careers within the healthcare industry. Many students and professionals are turning to online programs for flexibility and affordability. For those aiming to advance their clinical expertise, the cheapest dnp program options offer pathways for nurses seeking a Doctor of Nursing Practice degree without a hefty financial burden.

Pharmacy professionals can also benefit from accredited pharm d online programs, which are designed for those who aspire to become licensed pharmacists while balancing work and study.

If you are interested in the management side of healthcare, earning an accredited qualification through rhit programs online can help you establish a career in health information management. Alternatively, those looking for entry points into the medical field should explore billing and coding classes online, which prepare you for administrative roles in health organizations.

Each of these online pathways provides unique opportunities to diversify your skills and meet the evolving demands of the healthcare sector in the USA.

Best Scientists Citing Paola Guglielmelli

Trending Scientists

Recently Published Articles